Abintus is developing off-the-shelf genetic medicines that utilize in vivo cell engineering through a clinically proven Modular Delivery Platform to directly modify patients' immune cells for targeted therapies. These treatments aim to enhance the immune response against various diseases, including leukemia and solid tumors, by enabling precise gene expression and simultaneous engineering of diverse immune cell types.
Funding
$13.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell and gene therapies often require ex vivo modification of cells, which is complex, costly, and time-consuming, limiting patient access and posing logistical challenges. Traditional methods struggle to precisely target specific immune cell types and engineer multiple cell types simultaneously for comprehensive immune modulation.
Solution
Abintus Bio is developing off-the-shelf genetic medicines that utilize in vivo cell engineering to directly modify a patient's immune cells within the body. The company's Modular Delivery Platform (MDP) enables selective gene expression in targeted cell types through synthetic biology, allowing for precise control over the immune response. This approach facilitates the simultaneous engineering of diverse immune cell populations, such as CAR-NK, CAR-T, and Treg cells, to address various diseases. Abintus' in vivo approach aims to improve patient outcomes and access by simplifying the therapeutic process and reducing manufacturing complexities. The platform leverages clinically proven retroviral vector technology with a demonstrated safety profile in over 350 patients across multiple clinical trials.
Target Audience
The primary target audience includes patients with leukemia, lymphoma, solid tumors, autoimmune disorders, infectious diseases, and genetic diseases, as well as healthcare providers seeking off-the-shelf, in vivo cell engineering solutions.
Features
- Modular Delivery Platform (MDP) for in vivo cell engineering
- Highly selective gene expression targeting specific cell types/states via synthetic biology
- Ability to simultaneously engineer diverse active innate and adaptive immune cells
- Utilizes retroviral vectors with a demonstrated safety profile
- Applications across multiple gene delivery systems (AAV, lenti, adeno, retro)
- Potential for treating leukemia, solid tumors, autoimmune, infectious, and genetic diseases